ProBiotix Health partners with Velinoff Pharma to bring CholBiome® and CholBiome® X3 to Bulgarian market
OptiBiotix Health PLC (‘OptiBiotix’), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, has announced a new licensing agreement with Velinoff Pharma Ltd (‘Velinoff’) to distribute ProBiotix products CholBiome® and CholBiome®X3, which both contain the patented probiotic strain LPLDL®, to the Bulgarian market.
The non-exclusive deal between ProBiotix Health, a wholly owned subsidiary of OptiBiotix, and Velinoff will enable the sale of CholBiome and CholBiomeX3 to pharmacies, cardiologists, general practitioners and cardiologic clinics in Bulgaria. With the World Health Organisation estimating that the highest burden of disease in Bulgaria is linked to dietary risks, the science-backed innovation will help to combat cardiovascular disease, lower harmful cholesterol levels and reduce blood pressure in the region.
CholBiome contains LPLDL as the single active for cholesterol management, whereas CholBiomeX3 combines three ingredients, Monacolin K, Vitamin B3 and LPLDL, which synergistically work together to provide a multi-tiered enhanced approach. The inclusion of the patented probiotic strain LPLDL means CholBiome and CholBiomeX3 has supporting evidence into its efficacy through controlled human studies, reducing overall cholesterol levels by up to 36.7% and systolic blood pressure by up to 5.1%.
Steve Prescott, CEO of ProBiotix Health, commented: “We are pleased to announce the agreement with Velinoff, which will strengthen the presence of LPLDL in Bulgaria. The company’s local expertise, combined with a dedicated sales team to promote the sale of CholBiome and CholBiomeX3 in the Bulgarian market, is why Velinoff is our partner of choice.”
The new deal replaces the original agreement announced in September 2018 with an unnamed distributor, eliminating an intermediary in the supply chain with a more efficient route to market and a stronger relationship with Velinoff.
“The change to this agreement enables us to offer greater support to Velinoff to grow its sales of CholBiome and CholBiomeX3,” adds Steve Prescott. “This is all part of the next phase of our business cycle as we renegotiate partner agreements and focus our efforts on building a profitable business.”
Founded in 2018, Velinoff is a pharmaceutical marketing company and acts as representatives of pharmaceutical companies active in the advanced areas of biotechnology. Its core business is in discovering biotechnological innovations and therapies, affecting diseases such as cardiovascular and diabetes, to present the Bulgarian market with EU, EMA and US approved pharmacological care products.